Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04271488
PHASE1

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

Sponsor: Eisai Co., Ltd.

View on ClinicalTrials.gov

Summary

The primary purpose of the study is to evaluate the effects of mild and moderate hepatic impairment on PK of tasurgratinib after a single dose administration.

Official title: An Open-label Parallel-Group Study to Evaluate Pharmacokinetics of E7090 and Its Metabolite in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

Key Details

Gender

All

Age Range

20 Years - 79 Years

Study Type

INTERVENTIONAL

Enrollment

18

Start Date

2020-02-27

Completion Date

2026-11-30

Last Updated

2026-01-23

Healthy Volunteers

Yes

Interventions

DRUG

Tasurgratinib

Tasurgratinib oral tablet.

DRUG

Tasurgratinib

Tasurgratinib oral capsule.

Locations (8)

Eisai Trial Site #6

Hakata, Fukuoka, Japan

Eisai Trial Site #4

Kurume, Fukuoka, Japan

Eisai Trial Site #2

Yuhu, Oita Prefecture, Japan

Eisai Trial Site #3

Bukyo-ku, Tokyo, Japan

Eisai Trial Site #1

Mintato-ku, Tokyo, Japan

Eisai Trial Site #8

Shinjuku-ku, Tokyo, Japan

Eisai Trial Site #5

Kofu, Yamanashi, Japan

Eisai Trial Site #7

Kyoto, Japan